MedPath
Found 7 clinical trials|View Analysis
Sort by:

Web-Based Coping and Communication Skills Intervention in Improving Psychological Adaptation in Patients With Gynecological Cancer

Not Applicable
Withdrawn
Conditions
Stage II Ovarian Cancer AJCC v6 and v7
Endometrial Carcinoma
Stage 0 Fallopian Tube Cancer AJCC v7
Stage IA Fallopian Tube Cancer AJCC v6 and v7
Stage II Cervical Cancer AJCC v7
Stage IIA Cervical Cancer AJCC v7
Stage III Cervical Cancer AJCC v6 and v7
Stage IIIA Fallopian Tube Cancer AJCC v7
Stage IIIA Uterine Corpus Cancer AJCC v7
Stage IIIB Cervical Cancer AJCC v6 and v7
Interventions
Other: Internet-Based Intervention
Other: Quality-of-Life Assessment
Other: Questionnaire Administration
Other: Survey Administration
First Posted Date
2019-04-04
Last Posted Date
2021-04-19
Lead Sponsor
Rutgers, The State University of New Jersey
Registration Number
NCT03902379
Locations
🇺🇸

Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States

Testing AZD1775 inC Combination With Radiotherapy and Chemotherapy in Cervical, Upper Vaginal and Uterine Cancers

Phase 1
Terminated
Conditions
Cervical Carcinoma
Endometrioid Adenocarcinoma
Malignant Female Reproductive System Neoplasm
Recurrent Cervical Carcinoma
Stage I Uterine Corpus Cancer AJCC v7
Stage I Vaginal Cancer AJCC v6 and v7
Stage IA Uterine Corpus Cancer AJCC v7
Stage IB Cervical Cancer AJCC v6 and v7
Stage IB Uterine Corpus Cancer AJCC v7
Stage IB2 Cervical Cancer AJCC v6 and v7
Interventions
Drug: Adavosertib
Drug: Cisplatin
Radiation: External Beam Radiation Therapy
First Posted Date
2017-11-17
Last Posted Date
2024-02-20
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
10
Registration Number
NCT03345784
Locations
🇨🇦

University Health Network-Princess Margaret Hospital, Toronto, Ontario, Canada

🇺🇸

Rutgers Cancer Institute of New Jersey-Robert Wood Johnson University Hospital, New Brunswick, New Jersey, United States

🇺🇸

Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States

and more 5 locations

Testing the Addition of a New Anti-Cancer Drug, Triapine, to the Usual Chemotherapy Treatment (Cisplatin) During Radiation Therapy for Advanced-stage Cervical and Vaginal Cancers

Phase 3
Active, not recruiting
Conditions
Advanced Vaginal Adenocarcinoma
Stage II Cervical Cancer AJCC v7
Stage IIB Cervical Cancer AJCC v6 and v7
Stage IVA Vaginal Cancer AJCC v6 and v7
Unresectable Vaginal Carcinoma
Vaginal Adenocarcinoma
Cervical Adenocarcinoma
Stage IIIB Cervical Cancer AJCC v6 and v7
Stage IVA Cervical Cancer AJCC v6 and v7
Cervical Adenosquamous Carcinoma
Interventions
Radiation: Brachytherapy
Drug: Cisplatin
Radiation: External Beam Radiation Therapy
Radiation: Intensity-Modulated Radiation Therapy
Other: Laboratory Biomarker Analysis
Radiation: Radiation Therapy
Drug: Triapine
First Posted Date
2015-06-09
Last Posted Date
2024-12-27
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
450
Registration Number
NCT02466971
Locations
🇺🇸

Houston Methodist Hospital, Houston, Texas, United States

🇺🇸

Memorial Hermann Texas Medical Center, Houston, Texas, United States

🇺🇸

Methodist Willowbrook Hospital, Houston, Texas, United States

and more 380 locations

Chemoradiation Therapy and Ipilimumab in Treating Patients With Stages IB2-IIB or IIIB-IVA Cervical Cancer

Phase 1
Completed
Conditions
Stage IB2 Cervical Cancer AJCC v6 and v7
Cervical Adenosquamous Carcinoma
Stage II Cervical Cancer AJCC v7
Stage IIB Cervical Cancer AJCC v6 and v7
Stage IVA Cervical Cancer AJCC v6 and v7
Cervical Adenocarcinoma
Stage IIA Cervical Cancer AJCC v7
Stage IIIB Cervical Cancer AJCC v6 and v7
Cervical Squamous Cell Carcinoma, Not Otherwise Specified
Interventions
Drug: Cisplatin
Radiation: External Beam Radiation Therapy
Radiation: Internal Radiation Therapy
Biological: Ipilimumab
Other: Laboratory Biomarker Analysis
First Posted Date
2012-10-22
Last Posted Date
2020-09-02
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
34
Registration Number
NCT01711515
Locations
🇺🇸

UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange, California, United States

🇺🇸

University of California Davis Comprehensive Cancer Center, Sacramento, California, United States

🇺🇸

University of New Mexico Cancer Center, Albuquerque, New Mexico, United States

and more 13 locations

Cisplatin and Radiation Therapy With or Without Carboplatin and Paclitaxel in Patients With Locally Advanced Cervical Cancer

Phase 3
Completed
Conditions
Stage IB Cervical Cancer AJCC v6 and v7
Cervical Adenosquamous Carcinoma
Stage IIIB Cervical Cancer AJCC v6 and v7
Stage IIA Cervical Cancer AJCC v7
Cervical Squamous Cell Carcinoma, Not Otherwise Specified
Stage IVA Cervical Cancer AJCC v6 and v7
Cervical Adenocarcinoma
Stage IIB Cervical Cancer AJCC v6 and v7
Interventions
Radiation: Brachytherapy
Drug: Cisplatin
Drug: Carboplatin
Radiation: External Beam Radiation Therapy
Drug: Paclitaxel
Other: Quality-of-Life Assessment
First Posted Date
2011-08-11
Last Posted Date
2022-11-07
Lead Sponsor
GOG Foundation
Target Recruit Count
926
Registration Number
NCT01414608
Locations
🇺🇸

Grady Health System, Atlanta, Georgia, United States

🇺🇸

John H Stroger Jr Hospital of Cook County, Chicago, Illinois, United States

🇺🇸

UPMC-Shadyside Hospital, Pittsburgh, Pennsylvania, United States

and more 322 locations

Cisplatin and Radiation Therapy Followed by Paclitaxel and Carboplatin in Treating Patients With Stage IB-IVA Cervical Cancer

Phase 1
Conditions
Cervical Adenocarcinoma
Cervical Adenosquamous Carcinoma
Cervical Squamous Cell Carcinoma, Not Otherwise Specified
Stage IB Cervical Cancer AJCC v6 and v7
Stage IIA Cervical Cancer AJCC v7
Stage IIB Cervical Cancer AJCC v6 and v7
Stage IIIA Cervical Cancer AJCC v6 and v7
Stage IIIB Cervical Cancer AJCC v6 and v7
Stage IVA Cervical Cancer AJCC v6 and v7
Interventions
Drug: Carboplatin
Drug: Cisplatin
Radiation: External Beam Radiation Therapy
Radiation: Internal Radiation Therapy
Drug: Paclitaxel
First Posted Date
2011-02-14
Last Posted Date
2019-03-12
Lead Sponsor
Gynecologic Oncology Group
Target Recruit Count
45
Registration Number
NCT01295502
Locations
🇺🇸

Summa Akron City Hospital/Cooper Cancer Center, Akron, Ohio, United States

🇺🇸

Case Western Reserve University, Cleveland, Ohio, United States

🇺🇸

MetroHealth Medical Center, Cleveland, Ohio, United States

and more 11 locations

Bevacizumab, Radiation Therapy, and Cisplatin in Treating Patients With Previously Untreated Locally Advanced Cervical Cancer

Phase 2
Completed
Conditions
Cervical Squamous Cell Carcinoma, Not Otherwise Specified
Stage IB Cervical Cancer AJCC v6 and v7
Cervical Adenosquamous Carcinoma
Stage IIB Cervical Cancer AJCC v6 and v7
Stage III Cervical Cancer AJCC v6 and v7
Cervical Adenocarcinoma
Stage IIA Cervical Cancer AJCC v7
Interventions
Biological: Bevacizumab
Drug: Cisplatin
Radiation: External Beam Radiation Therapy
Radiation: Internal Radiation Therapy
First Posted Date
2006-08-29
Last Posted Date
2018-03-20
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
60
Registration Number
NCT00369122
Locations
🇺🇸

Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia, United States

🇺🇸

Providence Saint Joseph Medical Center/Disney Family Cancer Center, Burbank, California, United States

🇺🇸

University of California Davis Comprehensive Cancer Center, Sacramento, California, United States

and more 103 locations
© Copyright 2025. All Rights Reserved by MedPath